Opin vísindi

Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy

Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy


Title: Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy
Author: Sammar, Marei
Drobnjak, Tijana
Mandala, Maurizio
Gizurarson, Sveinbjörn
Huppertz, Berthold   orcid.org/0000-0003-4814-2158
Meiri, Hamutal   orcid.org/0000-0002-2272-5139
Date: 2019-07-01
Language: English
Scope:
School: Health Sciences
Department: Faculty of Pharmaceutical Sciences
Series: International Journal of Molecular Sciences; 20(13)
ISSN: 1661-6596
DOI: https://doi.org/10.3390/ijms20133192
Subject: Biomarkers; ENOS; FGR; Gal 10; Gal 13; Gal 14; Gal 16; Placental protein 13; Polymorphism; Preeclampsia; Risk prediction; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic Chemistry
URI: https://hdl.handle.net/20.500.11815/3448

Show full item record

Citation:

Sammar , M , Drobnjak , T , Mandala , M , Gizurarson , S , Huppertz , B & Meiri , H 2019 , ' Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy ' , International Journal of Molecular Sciences , vol. 20 , no. 13 , 3192 . https://doi.org/10.3390/ijms20133192

Abstract:

Galectins regulate cell growth, proliferation, differentiation, apoptosis, signal transduction, mRNA splicing, and interactions with the extracellular matrix. Here we focus on the galectins in the reproductive system, particularly on a group of six galectins that first appears in anthropoid primates in conjunction with the evolution of highly invasive placentation and long gestation. Of these six, placental protein 13 (PP13, galectin 13) interacts with glycoproteins and glycolipids to enable successful pregnancy. PP13 is related to the development of a major obstetric syndrome, preeclampsia, a life-threatening complication of pregnancy which affects ten million pregnant women globally. Preeclampsia is characterized by hypertension, proteinuria, and organ failure, and is often accompanied by fetal loss and major newborn disabilities. PP13 facilitates the expansion of uterine arteries and veins during pregnancy in an endothelial cell-dependent manner, via the eNOS and prostaglandin signaling pathways. PP13 acts through its carbohydrate recognition domain that binds to sugar residues of extracellular and connective tissue molecules, thus inducing structural stabilization of vessel expansion. Further, decidual PP13 aggregates may serve as a decoy that induces white blood cell apoptosis, contributing to the mother’s immune tolerance to pregnancy. Lower first trimester PP13 level is one of the biomarkers to predict the subsequent risk to develop preeclampsia, while its molecular mutations/polymorphisms that are associated with reduced PP13 expression are accompanied by higher rates of preeclampsia We propose a targeted PP13 replenishing therapy to fight preeclampsia in carriers of these mutations.

Description:

Funding Funding: This research was funded by Daniel Turnberg Fellowship, UK Academy of Medical Sciences and the EU COST action CA16113 – CkiniMark to M.S. This study was also sponsored in part by the European Union (FP7) through the ASPRE project (601852) to H.M., S.G. and T.D. were sponsored by Hananja ehf, and Icelandic Research Fund (Rannís), grant no. 163403-052. Publisher Copyright: © 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Files in this item

This item appears in the following Collection(s)